Johnson & Johnson has formed a consortium, The Innovative Medicines Initiative (IMI), with global research institutions and non-government organizations to work with Janssen to accelerate the development of its Ebola vaccine regimen. The IMI plans to award grants totaling more than €100 million from the Ebola+ program to support the development, manufacture and patient education for the vaccine regimen.   Funding for the program comes in part from Horizon 2020, the EU’s research and in...